Cancer Antibodies Vaccines/Adjuvants & Delivery

17-19 September 2014, University of Lausanne/CHUV, Lausanne, Switzerland

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Wednesday 17th September

08.45 Onwards
Registration

09.55-10.00
Welcome to Lausanne & Opening Remarks
Daniel E. Speiser (University of Lausanne, Lausanne, Switzerland)

SESSION 1:
OPENING PLENARY

Moderator: Daniel E. Speiser (University of Lausanne, Lausanne, Switzerland)

10.00-10.45
‘Role of IL-1a in Cancer’
Thomas M. Kundig (University Hospital Zurich, Zurich, Switzerland)

10.45-11.30
‘Lessons from immunotherapeutic developments against 5T4 oncofoetal antigen’
Peter Stern (University of Manchester, Manchester, UK)

11.30-12.00
‘Phase I/II trial of a novel antibody DNA immunotherapy, targeting CD64, in the treatment of melanoma’
Lindy Durrant (University of Nottingham, Nottingham, UK)

12.00-12.30
‘Towards a glioma vaccine’
Virgil Schijns (Epitopoietic Research Corporation (ERC) / University of Wageningen, Wageningen, The Netherlands)

12.30-14.00
Lunch Break

SESSION 2:
PLENARY

Moderator: Lindy Durrant (University of Nottingham, Nottingham, UK)

14.00-14.30
‘Vaccination against cancer, present and future’
Daniel E. Speiser (University of Lausanne, Lausanne, Switzerland)

14.30-15.00
‘Reverse proteomics for the discovery of novel cancer biomarkers and mAb therapies’
Guido Grandi (Novartis vaccines, Siena, Italy)

15.00-15.30
‘Obinutuzumab (GAZYVARO): A novel glycoengineered type II CD20 antibody for the treatment of chronic lympocytic leukemia (CLL)’
Christian Klein (Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Zurich, Switzerland)

15.30-15.45
Tea Break

SESSION 3:
ANTIBODIES FOR CANCER THERAPY

Moderator: Mark C. Glassy (Nascent Biotech, Inc., San Diego, California, USA)

15.45-16.15
‘KK1, a natural humabn IgM for adenocarcinomas’
Mark C. Glassy (Nascent Biotech, Inc. / Integrated Medical Sciences Association Foundation, San Diego, California, USA)

16.15-16.35
‘Novel anti-glycolipid mabs for tumour therapy’
Mireille Vankemmelbeke (University of Nottingham, Nottingham, UK)

16.35-16.55
‘Generation and functional characterization of synthetic antibodies specific to colon cancer stem cell antigens’
Jason Moffat (University of Toronto, Toronto, Canada)

16.55-17.15
‘Novel mechanism of action of anti-CTLA-4 mAb therapy in patients with advanced melanoma’
Emanuela Romano (University of Lausanne, Lausanne, Switzerland)

17.15-17.45
‘Personalized vector vaccines expressing neoepitopes’
Lukas Flatz (Institute of Immunobiology, Kantonsspital St. Gallen, Switzerland)

 

CAVAD 2014 Delegates

Login details will be supplied after you have registered for the event.


CAVAD 2014 Sponsors

  • F-star
  • InCellArt
  • Nascent Biologics
  • ElsaLys Biotech
  • Aldevron
  • DNAvaccine.com
  • ImmunoGen
  • NatureGeneTherapy.com
  • Pantec Biosolutions
  • Inovio Pharmaceuticals

CAVAD 2014 Downloads

CAVAD 2014 Leaflet

CAVAD 2014 Mailing List

Name
E-mail Address
What is 3+2-1?